Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia
Mike is an experienced business development consultant, residing in North Carolina, US. Mike has been in the clinical space for over 13 years with experience in preclinical and clinical (Phase I-IV). Mike also has a thorough understanding of the Australian R & D Tax Incentive ...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will attend World Vaccine Congress in Washington DC (April 1-4, 2024) and share the latest clinical trial client news including the Uvax Bio announcement. (Booth #267)
YOUR BIOTECH CRO PARTNER FOR QUALITY EARLY PHASE CLINICAL TRIALS Avance Clinical offers a comprehensive range of clinical research organization (CRO) services in Australia and New Zealand, strategically positioned to facilitate groundbreaking trials, and expedite the path to regulatory approval. With our global headquarters based ...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, announces two key appointments in the US to support its continued global growth.
EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023
The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.
Avance Clinical is a full-service Contract Research Organization (CRO) with clinical operations in Australia, New Zealand, Asia, North America, and Europe.
Level 22, 91 King William Street
Adelaide, SA
Australia 5000
Phone: +61 8 8249 4788
For all media enquiries: media@avancecro.com